Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

  • Revenue in USD (TTM)42.56bn
  • Net income in USD4.26bn
  • Incorporated1999
  • Employees68.63k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 208 047 5000
  • Fax+44 208 047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GSK:LSE since
announced
Transaction
value
CELLphenomics GmbHDeal completed16 Jan 202516 Jan 2025Deal completed6.10%--
IDRx IncDeal completed13 Jan 202513 Jan 2025Deal completed4.37%1.15bn
Data delayed at least 20 minutes, as of Jul 11 2025 16:09 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biogen Inc9.82bn1.48bn19.67bn7.61k13.251.168.902.0010.1310.1367.18115.900.35961.004.911,290,782.005.429.026.4210.6975.5881.0015.0721.251.014.810.27060.00-1.62-7.6240.57-22.63-11.68--
Royalty Pharma plc2.26bn1.09bn20.15bn99.0014.623.0460.278.902.452.453.8411.810.1342--98.4022,867,120.0010.487.5613.6210.21----78.1255.06--14.510.437646.51-3.864.52-24.31-18.227.80--
Alnylam Pharmaceuticals, Inc.2.35bn-269.70m41.06bn2.23k--355.53--17.49-2.09-2.0918.270.88580.58424.129.701,052,959.00-6.71-20.07-8.96-25.5186.0184.18-11.49-55.192.98-0.46270.8988--22.9759.2136.82---24.55--
Regeneron Pharmaceuticals Inc14.09bn4.50bn61.30bn15.11k14.452.0912.274.3539.3039.30123.45271.600.39170.63472.61932,457.3012.5118.5213.8921.1386.6987.2231.9437.924.03--0.0843--8.2712.5511.6115.8415.46--
Zoetis Inc9.29bn2.52bn68.99bn13.80k27.8314.8522.867.435.575.5720.5410.440.65291.077.00672,898.6017.7715.2521.8318.3170.9870.1827.2226.321.0421.140.585628.938.338.146.0610.637.3221.37
GSK plc (ADR)42.56bn4.26bn78.10bn68.63k18.604.158.421.842.062.0620.649.220.52891.514.54620,156.906.116.269.149.8672.0170.7511.5515.560.580115.020.574580.463.46-1.45-47.75-11.136.63--
Bristol-Myers Squibb Co47.64bn5.42bn95.36bn34.10k17.595.487.062.002.662.6623.448.540.49764.275.121,396,950.005.680.65367.690.817574.6976.6311.411.521.177.390.7402678.247.3213.06-211.50--8.347.91
Data as of Jul 11 2025. Currency figures normalised to GSK plc's reporting currency: US Dollar USD

Institutional shareholders

11.27%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Mar 202578.65m3.80%
Fisher Asset Management LLCas of 31 Mar 202530.03m1.45%
Strategic Advisers LLCas of 31 Mar 202527.29m1.32%
PRIMECAP Management Co.as of 31 Mar 202525.71m1.24%
Fidelity Management & Research Co. LLCas of 31 Mar 202523.32m1.13%
JTC Plc /Private Banking/as of 31 Mar 202515.26m0.74%
FIAM LLCas of 31 Mar 20259.52m0.46%
Goldman Sachs Asset Management LPas of 31 Mar 20258.47m0.41%
T. Rowe Price International Ltd.as of 31 Mar 20257.72m0.37%
UBS Securities LLCas of 31 Mar 20257.49m0.36%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.